Literature DB >> 17115047

Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.

Fulvio Mavilio1, Graziella Pellegrini, Stefano Ferrari, Francesca Di Nunzio, Enzo Di Iorio, Alessandra Recchia, Giulietta Maruggi, Giuliana Ferrari, Elena Provasi, Chiara Bonini, Sergio Capurro, Andrea Conti, Cristina Magnoni, Alberto Giannetti, Michele De Luca.   

Abstract

The continuous renewal of human epidermis is sustained by stem cells contained in the epidermal basal layer and in hair follicles. Cultured keratinocyte stem cells, known as holoclones, generate sheets of epithelium used to restore severe skin, mucosal and corneal defects. Mutations in genes encoding the basement membrane component laminin 5 (LAM5) cause junctional epidermolysis bullosa (JEB), a devastating and often fatal skin adhesion disorder. Epidermal stem cells from an adult patient affected by LAM5-beta3-deficient JEB were transduced with a retroviral vector expressing LAMB3 cDNA (encoding LAM5-beta3), and used to prepare genetically corrected cultured epidermal grafts. Nine grafts were transplanted onto surgically prepared regions of the patient's legs. Engraftment was complete after 8 d. Synthesis and proper assembly of normal levels of functional LAM5 were observed, together with the development of a firmly adherent epidermis that remained stable for the duration of the follow-up (1 year) in the absence of blisters, infections, inflammation or immune response. Retroviral integration site analysis indicated that the regenerated epidermis is maintained by a defined repertoire of transduced stem cells. These data show that ex vivo gene therapy of JEB is feasible and leads to full functional correction of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17115047     DOI: 10.1038/nm1504

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  199 in total

Review 1.  Induced pluripotent stem cells in dermatology: potentials, advances, and limitations.

Authors:  Ganna Bilousova; Dennis R Roop
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

2.  Early intra-amniotic gene transfer using lentiviral vector improves skin blistering phenotype in a murine model of Herlitz junctional epidermolysis bullosa.

Authors:  M Endo; P W Zoltick; A Radu; Q Jiang; J Qiujie; C Matsui; P M Marinkovich; J McGrath; K Tamai; J Uitto; A W Flake
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

3.  Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts.

Authors:  Arianna Moiani; Ylenia Paleari; Daniela Sartori; Riccardo Mezzadra; Annarita Miccio; Claudia Cattoglio; Fabienne Cocchiarella; Maria Rosa Lidonnici; Giuliana Ferrari; Fulvio Mavilio
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

4.  Development and homeostasis of the skin epidermis.

Authors:  Panagiota A Sotiropoulou; Cedric Blanpain
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-07-01       Impact factor: 10.005

Review 5.  Revertant mosaicism in skin: natural gene therapy.

Authors:  Joey E Lai-Cheong; John A McGrath; Jouni Uitto
Journal:  Trends Mol Med       Date:  2010-12-29       Impact factor: 11.951

6.  Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis.

Authors:  Stefan K Drexler; Luca Bonsignore; Mark Masin; Aubry Tardivel; Rene Jackstadt; Heiko Hermeking; Pascal Schneider; Olaf Gross; Jurg Tschopp; Amir S Yazdi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

7.  Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes.

Authors:  Masami Niiya; Masayuki Endo; Dezhi Shang; Philip W Zoltick; Nidal E Muvarak; Wenjing Cao; Sheng-Yu Jin; Christopher G Skipwith; David G Motto; Alan W Flake; X Long Zheng
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

Review 8.  Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix.

Authors:  Jakub Tolar; John E Wagner
Journal:  Lancet       Date:  2013-10-05       Impact factor: 79.321

9.  Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells.

Authors:  Jakub Tolar; Akemi Ishida-Yamamoto; Megan Riddle; Ron T McElmurry; Mark Osborn; Lily Xia; Troy Lund; Catherine Slattery; Jouni Uitto; Angela M Christiano; John E Wagner; Bruce R Blazar
Journal:  Blood       Date:  2008-10-27       Impact factor: 22.113

10.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.